Reassessing the Philip Morris v Australia Plain Packaging Dispute in International Economic Law

Abstract

This article reassesses the legal significance of the tobacco plain packaging disputes arising from Australia’s Tobacco Plain Packaging Act 2011 through the integrated lenses of international trade law, intellectual property law, investment treaty law, and constitutional property doctrine. Rather than treating Philip Morris v Australia as a simple conflict between trademark protection and public health, the article argues that the dispute is best understood as a test of the regulatory space preserved for states within an increasingly constitutionalised system of international economic law. Using doctrinal legal research, treaty interpretation under Articles 31–33 of the Vienna Convention on the Law of Treaties, comparative case analysis, and a public-law approach to investment adjudication, the article examines three interconnected proceedings: the High Court of Australia’s decision in JT International SA v Commonwealth; the WTO disputes concerning Australia’s tobacco plain packaging measures; and the investor–state arbitration initiated by Philip Morris Asia under the 1993 Australia–Hong Kong investment treaty. It further compares the Australian dispute with Philip Morris v Uruguay, Methanex v United States, Saluka v Czech Republic, Chemtura v Canada, and Tecmed v Mexico. The analysis demonstrates that trademark and investment protections do not create an affirmative entitlement to an unchanging regulatory environment. The High Court’s distinction between deprivation and acquisition, the WTO’s interpretation of “unjustifiably” in TRIPS Article 20, and the investment tribunal’s rejection of post-dispute treaty shopping collectively point toward a model of bounded economic rights: private rights remain legally protected, but their exercise is conditioned by legitimate, non-discriminatory, evidence-based regulation. The article concludes that the enduring contribution of the Australian plain packaging litigation lies not in establishing an unlimited public-health exception, but in clarifying the legal techniques through which regulatory autonomy can coexist with international economic commitments.